23 assets in Ductal Breast Carcinoma In Situ

Therapeutic assets addressing Ductal Breast Carcinoma In Situ, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anastrozole Ductal Breast Carcinoma In Situ	Alliance for Clinical Trials in Oncology	P3	BB (64)
Letrozole Ductal Breast Carcinoma In Situ	Alliance for Clinical Trials in Oncology	P3	BB (64)
Metformin Ductal Breast Carcinoma In Situ	M.D. Anderson Cancer Center	P3	BB (64)
Tamoxifen Ductal Breast Carcinoma In Situ	National Cancer Institute (NCI)	P3	BB (64)
(Z)-Endoxifen Ductal Breast Carcinoma In Situ	Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)	P2	BB (64)
Exemestane Ductal Breast Carcinoma In Situ	Alliance for Clinical Trials in Oncology	P3	B (63)
Gm-Csf Ductal Breast Carcinoma In Situ	Mayo Clinic	P2	B (63)
Z/E 4-Hydroxy Tamoxifen Ductal Breast Carcinoma In Situ	Northwestern University	P2	B (62)
Acolbifene Ductal Breast Carcinoma In Situ	National Cancer Institute (NCI)	P2	CCC (53)
Brc-001 Ductal Breast Carcinoma In Situ	City of Hope Medical Center	P2	CCC (53)
Elacestrant Ductal Breast Carcinoma In Situ	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Fapi-46 Ductal Breast Carcinoma In Situ	Universität Münster	P2	CCC (53)
Fezolinetant Ductal Breast Carcinoma In Situ	University of Michigan Rogel Cancer Center	P2	CCC (53)
Magtrace Ductal Breast Carcinoma In Situ	University of Florida	P2	CCC (53)
N-Desmethyl-4-Hydroxytamoxifen Ductal Breast Carcinoma In Situ	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Testosterone Undecylate Ductal Breast Carcinoma In Situ	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-Oh (Ls301) Ductal Breast Carcinoma In Situ	Integro Theranostics	P1/2	CCC (51)
Omega-3-Acid Ethyl Esters Ductal Breast Carcinoma In Situ	National Cancer Institute (NCI)	P2	CCC (48)
can1012 Ductal Breast Carcinoma In Situ	Providence Health & Services	P1	CC (43)
muc1 peptide vaccine Ductal Breast Carcinoma In Situ	Finn, Olivera, PhD	P1	CC (43)
Multi-Epitope Her2 Peptide Vaccine H2Nvac Ductal Breast Carcinoma In Situ	Mayo Clinic	P1	CC (43)
Mrna-2752 Ductal Breast Carcinoma In Situ	Laura Esserman	Early P1	C (39)
Pembrolizumab Ductal Breast Carcinoma In Situ	Laura Esserman	Early P1	C (39)